Atara Biotherapeutics (ATRA) Cash from Operations (2013 - 2026)

Atara Biotherapeutics has reported Cash from Operations for 14 years, with the latest figure at 3073000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 89.08% year-over-year to 3073000.0; the trailing twelve-month figure through Mar 2026 stood at 25875000.0 (up 61.52% YoY), and the FY2025 full-year result was 50940000.0, up 25.87% from the prior year.
• Cash from Operations for Q1 2026 stood at 3073000.0, up from 5697000.0 in the prior quarter.
• The five-year high for Cash from Operations was 3073000.0 in Q1 2026, with the low at 84529000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 34478647.06 across 5 years, with a median of 29612000.0 in 2024.
• Annual changes were most pronounced in 2024 — Cash from Operations soared 92.23% — and 2025, when it sank 145.35%.
• Atara Biotherapeutics' Cash from Operations stood at 56880000.0 in 2022, then grew by 11.38% to 50406000.0 in 2023, then surged by 51.45% to 24471000.0 in 2024, then soared by 76.72% to 5697000.0 in 2025, then jumped by 46.06% to 3073000.0 in 2026.
• The last three Cash from Operations figures came in at 3073000.0 (Q1 2026), 5697000.0 (Q4 2025), and 9787000.0 (Q3 2025), per Business Quant data.